WebElahere will be supplied as a single-dose vial containing 100 mg of mirvetuximab soravtansine in 20 mL (5 mg/mL) of sterile solution. The proposed dose is 6 mg/kg adjusted ideal body weight administered once every 3 weeks (21-day cycle) as an intravenous infusion until disease WebNov 15, 2024 · Patients received a 6mg/kg dose of mirvetuximab soravtansine-gynx through an intravenous infusion every three weeks until disease progression or unacceptable toxicity. Researchers conducted tumor response assessments every six weeks for the first 36 weeks and every 12 weeks thereafter. ... "The approval of ELAHERE is significant for …
Meghan Berkenstock on Managing Ocular Toxicities With ADCs in …
WebIndicated for adults with folate receptor–alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received 1-3 prior … WebThe recommended dose of ELAHERE is 6 mg/kg adjusted ideal body weight (AIBW) administered once every 3 weeks (21-day cycle) as an IV infusion until disease progression or unacceptable toxicity The total dose of … hauling groceries
Elahere: Uses, Dosage, Side Effects & Warnings - Drugs.com
WebJan 10, 2024 · Elahere (mirvetuximab soravtansine-gynx) injection to treat patients with recurrent ovarian cancer that is resistant to platinum therapy. Enjaymo (sutimlimab-jome) injection to decrease the need... WebApr 10, 2024 · Meghan K. Berkenstock, MD, discusses the growing need for strong collaboration between ophthalmologists and gynecologic oncology care teams. With the approval of tisotumab vedotin-tftv (Tivdak) for patients with metastatic cervical cancer and mirvetuximab soravtansine -gynx (Elahere) for patients with platinum-resistant ovarian … WebJan 6, 2024 · Patients received mirvetuximab soravtansine-gynx 6 mg/kg, based on adjusted ideal body weight, as an intravenous infusion every three weeks until disease progression or unacceptable toxicity. bop gun ice